Scarica l'app Stockscreener
6.50
1.88%
0.12
Dopo l'orario di chiusura:
6.35
-0.15
-2.31%
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada
Taysha’s TSHA-102 Rett Data Links Clinical Promise To Future Revenue - Sahm
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15 - Moomoo
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Needham -- Price Target Holds at $12.00 - GuruFocus
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to sales forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Baird -- Price Target Raised to $15.00 - GuruFocus
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15 - Moomoo
Price to sales forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Baird raises Taysha Gene Therapies price target to $15 - scanx.trade
Price to book forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
Enterprise value to EBIT forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to earnings forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13, Implies 105% Upside - TradingView
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell 3000E Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell Microcap Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Rett Data and $200 Million Raise Might Change The Case For Investing In Taysha (TSHA) - Sahm
Taysha Gene Therapies launches $200M public offering; shares down - MSN
Taysha Gene Therapies Inc (TSHA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Taysha Gene Therapies Announces Major Equity Financing Deal - The Globe and Mail
Taysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200M - MSN
Form 424B5 Taysha Gene Therapies Inc For: 25 June By Investing.com - Investing.com Nigeria
Taysha Gene Therapies to present Rett syndrome data at conference By Investing.com - Investing.com Nigeria
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting - Investing News Network
Taysha Gene Therapies to present Rett syndrome data at conference - Investing.com
Taysha Gene Therapies Prices Equity Offering for ~$187.4 Million Net, Grants 5 Million Share Option - TradingView
Taysha Gene Therapies (NASDAQ: TSHA) prices $200M equity raise with warrants - Stock Titan
Taysha Gene Therapies, Inc. to present TSHA-102 Rett syndrome clinical program at scientific meeting - Traders Union
Taysha Gene Therapies (TSHA) priced 32.5M-share offering; $187M net proceeds - Stock Titan
Taysha Gene Therapies Announces Multiple Presentations - GlobeNewswire
Taysha Gene Therapies Down Over 11%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Taysha Gene Therapies (TSHA) Shares Fall 9.2% Following $200M Pu - GuruFocus
Taysha Gene Therapies, Inc. Actuals & Estimates (NASDAQ:TSHA) - TradingView
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session - Benzinga
Taysha Gene Therapies stock tumbles on public offering pricing By Investing.com - Investing.com Australia
Taysha Gene Therapies stock tumbles on $200M stock offering By Investing.com - Investing.com India
TSHA Secures New Offering at Discounted Price - GuruFocus
Taysha Gene Therapies prices $200M stock offering at $6 per share - Investing.com South Africa
Taysha Gene Therapies: Offering Expected to Close on or Abour June 26 >TSHA - Moomoo
Taysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Taysha prices $200M offering as closing nears June 26 - Stock Titan
Taysha Gene Therapies Announces Pricing Of Public Offering Of Common Stock And Pre-Funded Warrants - TradingView
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Taysha Gene Therapies launches $200 million stock offering - Investing.com UK
Taysha Gene Therapies Inc Files For Mixed Shelf Offering Of Up To $200 MillionSEC Filing - TradingView
Form 424B5 Taysha Gene Therapies Inc For: 24 June By Investing.com - Investing.com Australia
Taysha presents TSHA-102 data at 2026 IRSF Rett Syndrome meeting - scanx.trade
Taysha Gene Therapies (TSHA) files $200M common stock and pre-funded warrants offering - Stock Titan
Taysha Gene Therapies stock tumbles on $200M stock offering - Investing.com
9 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Taysha Gene Therapies prices $200M public offering of common stock - scanx.trade
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):